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Purpose. With the aim of developing multivalent vaccines for single-
injection, we examined the feasibility of combining antigens in bio-
degradable microspheres. Such vaccines are expected to improve vac-
cination coverage by reducing the number of vaccination sessions
required to generate immunity.
Methods. Mono- and multivalent vaccines of Haemophilus influenzae
type b (Hib) conjugate, diphtheria toxoid (DT), tetanus toxoid (TT),
and pertussis toxin (PT) in poly (lactic acid) and poly(lactic-coglycolic
acid) microspheres were prepared by spray drying, and the influence
of coencapsulated antigens and excipients on antigen loading, release,
and stability was examined. Two tetravalent formulations were tested
in guinea pigs.
Results. Monovalent Hib and PT vaccines showed loading efficien-
cies of 10% (Hib) and 30% (PT) in both polymers. The loading
efficiencies increased upon addition of trehalose and, even more,
when the antigens were coencapsulated in di- and trivalent combina-
tions. Highest loading efficiencies (>80%) were achieved with triva-
lent formulations (DT + PT + Hib) that also contained coencapsu-
lated albumin. The percentage of antigen released during 24 h of
incubation was typically 10–40% and decreased as loading efficiency
increased. Enzyme-linked immunosorbent assay (ELISA) data re-
vealed that TT, DT, and PT remained antigenic throughout the en-
capsulation and subsequent release processes. Finally, all antigens
maintained their immunogenicity, since strong and sustained anti-
body responses were elicited after a single injection of tetravalent
microsphere vaccines (DT + TT + PT + Hib) in guinea pigs.
Conclusions. This study reveals technologic benefit as well as an
immunological potential of multivalent single-injection microsphere
vaccines. The results support our hypothesis that coencapsulation of
several antigens may intrinsically improve entrapment of antigenic
and immunogenic antigen probably by virtue of increased protein
concentration during microencapsulation leading to mutual stabiliza-
tion of the components.
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INTRODUCTION
The number of administrations required for most vac-
cines to induce protective immunity limits the vaccination
coverage and success especially in countries with insufficient
medical logistics. According to the World Health Organisa-
tion (WHO), operational costs of vaccination campaigns con-
tribute to almost 90% of the total costs, and dropout rates
from the first to the consecutive doses of vaccines of up to
70% have been registered. The availability of multivalent vac-
cines already improved vaccination campaigns in the past, but
the development of single-injection (or single-dose) vaccines
may further simplify vaccination. Indeed, antigens embedded
in biodegradable poly (lactic acid) (PLA) and poly(lactic-
coglycolic acid) (PLGA) microspheres (reviewed in [1]) have
been shown to stimulate long-lasting antibody responses (2–
4) as well as cytotoxic T lymphocytes (5,6).
While multivalent combined vaccines based on diphthe-
ria (DT), tetanus (TT), pertussis (PT), Haemophilus influen-
zae type b (Hib), polio, and hepatitis B or measles, mumps,
and rubella antigens are already in use, limited data on mul-
tivalent vaccines based on polymeric microspheres is avail-
able (2,3) as previous studies were almost exclusively re-
stricted to the encapsulation of a single antigen type. Never-
theless, the coencapsulation of multiple antigens may raise
specific constraints concerning the biophysical stability and
the immunogenicity of the vaccines, which may not be pre-
dictable from the properties of the individual vaccine compo-
nents but which may result from interactions between differ-
ent components (7). The combination of antigens in conven-
tional formulations either decreases (8,9) or increases (10) the
immunogenicity of individual components, and similar fea-
tures may be expected in microsphere-based multivalent vac-
cines.
Nevertheless, previous studies have demonstrated the
stabilising effect of proteins (e.g., albumin and gelatine) on
microencapsulated antigens. Therefore, the main objectives
of this investigation were to study whether successful techno-
logic concepts for TT and DT (4,11) could be transferred to
Hib and PT antigens. Furthermore, we aimed at testing the
hypothesis that coencapsulation of several antigens into
PLGA microspheres may improve the encapsulation effi-
ciency of intact material by virtue of increased total protein
content during encapsulation. Our results show that multiva-
lent microsphere vaccines are technologically feasible. Coen-
capsulation of multiple antigens can even enhance the loading
efficiency of antigenic protein in the microspheres. Further-
more, tetravalent single-injection microsphere vaccines con-
taining DT, TT, PT and Hib were highly immunogenic for all
antigens as measured by induction of antibodies in guinea pigs.
EXPERIMENTAL
Materials
Hib conjugated to TT, genetically attenuated PT, DT,
and column-purified TT were from Berna, the Swiss Serum
and Vaccine Institute (Berne, Switzerland), Chiron Vaccines
(Siena, Italy), Aventis Pasteur (Lyon, France), and Massa-
chusetts Public Health Biologic Laboratories (Boston, MA,
USA), respectively. PLGA 50:50 and PLA with intrinsic viscosi-
ties of approximately. 0.2 dL/g were purchased from Boeh-
ringer-Ingelheim (Ingelheim, Germany). Trehalose was from
Quadrant (Ruddington, United Kingdom) and bovine serum
albumin from Fluka (Buchs, Switzerland). The immunologi-
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cal adjuvant Alhydrogel, an aluminium hydroxide (alum),
was from Superfos (Vedbaek, Denmark). All other sub-
stances were of pharmaceutical or analytical grade.
Methods
Preparation of Microspheres
Volumes of 2.0–2.5 mL of aqueous antigen or antigen
mixtures were mixed with 20 mL polymer solution in dichlo-
romethane (10%, w/v). In certain experiments, albumin and
trehalose were also added to the aqueous phase. The W/O
mixture was homogenised on ice by ultrasonication (2 × 10 s,
20 kHz) and spray-dried with a Büchi 190 Mini Spray Dryer
(Flawil, Switzerland) at a rate of 2 mL/min and an inlet tem-
perature of 38–39°C. The microspheres were collected and
washed in aqueous poloxamer 188 (0.1%), passed through a
50 m mesh sieve, collected on a 0.8 m cellulose acetate
filter, washed with heptane, and dried at room temperature
and 50 mbar for 12 h. All formulations (n  1–2) showed a
regular and spherical microsphere morphology, with particle
sizes in the range of 0.5 to 5 m as measured by visible light
microscopy and laser light scattering.
Antigen Loading and in Vitro Release
For determination of protein and antigen loading, the
antigens were extracted from 100 mg microspheres as previ-
ously described (11), and the results were expressed in per-
cent relative to the nominal antigen loadings. Antigen burst
release from 80 mg microspheres in 4 mL PBS was analyzed
after 24 h, (11), and the results expressed relative to the de-
termined antigen loadings. Both loading and release determi-
nations were performed in triplicate from one single batch of
microspheres.
Determination of Hib and PT Content by Fluorimetry and
Bial Assay
When encapsulated individually or together with treha-
lose, Hib, and PT were assayed fluorimetrically using an ex-
citation wavelength of 280 nm and emission wavelengths of
320 (Hib) and 340 (PT) nm. In combination with other anti-
gens or albumin, ribosyl content of Hib was quantified with
the orcinol reaction as proposed by Bial (12); due to interfer-
ence, the Bial method could not be applied to vaccine formu-
lations containing trehalose. Briefly, 0.6 mL 0.1% FeCl3 in
concentrated hydrochloric acid and 60 l of 100 mg/mL or-
cinol in 95% ethanol were added to 0.6 mL of the Hib solu-
tion. The samples were heated 40 min at 95°C and cooled to
room temperature before measured photometrically at 670 nm.
Determination of DT, TT and PT Antigenicity by ELISA
In combination with other antigens or albumin, DT, TT,
and PT were quantified by ELISA. Flat-bottom microtiter
96-well plates were used, which were washed thrice with
0.05% polysorbate 20 in 0.15 M phosphate-buffered saline of
pH 7.4 (PBS) after each incubation step. DT (13) and TT (14)
content were measured by ELISA as previously described.
For PT analysis, the plates were coated with an anti-PT mono-
clonal antibody (NIBSC; Potters Bar; UK) in 0.05 M carbon-
ate buffer of pH 9.6 by overnight incubation at 4°C. After 1 h
at 37°C with PBS containing 0.5% albumin (PBS-BSA), the
plates were incubated at 37°C for 2 h with serial dilutions of
standard and test solutions of PT. Further incubations with
sheep anti-PT antiserum (NIBSC code no. 97/572) in PBS-
BSA (37°C, 2 h), alkaline phosphatase conjugated donkey
antisheep IgG (The Binding Site; Birmingham, UK) in PBS-
BSA (37°C, 2 h), and 1 mg/mL p-nitrophenyl phosphate
(Sigma Chemical; St. Louis, MO, USA) in 10% diethanol-
amine buffer of pH 9.6 (20°C, 40 min) were conducted before
the optical density was measured at 405 nm (Thermomax,
Molecular Devices; Menlo Park, CA, USA). No analytical
interference in the specific ELISA reactivity for PT, DT, or
TT was observed in the presence of any other antigen or the
additives trehalose and albumin at relevant concentrations
(data not shown).
Immunization of Guinea Pigs and Determination of
Antibodies by ELISA
Groups of female guinea pigs (250–300 g, strain DH)
were immunized subcutaneously with either of two tetrava-
lent microspheres vaccine formulations dispersed in 0.5 mL
aqueous alum (0.035 mg Al3+ per dose per animal). The two
formulations tested differed in their antigen loading (high vs.
low nominal antigen loading) as well as in their relative con-
tent, i.e., different actual DT/PT, DT/Hib, TT/PT, TT/Hib, or
PT/Hib ratios caused by different encapsulation efficiencies
of the individual antigens (Fig. 1 and Fig. 2). An alum-
adsorbed commercial tetravalent vaccine was used as positive
control (50 and 20 Lf/mL DT and TT, respectively; 8 g/mL
chemically detoxified PT, but the vaccine also contains fila-
mentous hemagglutinin and pertactin; 30 g/mL Hib conju-
gated to TT), but at a higher alum dose (0.06 mg Al3+). Ani-
mals were bled by cardiac puncture under anesthesia 2–16
weeks post immunization, and serum was prepared from clot-
ted blood and stored at −20°C.
Fig. 1. Loading efficiency of antigens in two tetravalent poly (d, l-
lactic-coglycolic acid) 50:50 microsphere vaccines with high (filled
bars) and low (open bars) nominal antigen loadings. Microspheres
were prepared with nominally 0.46 or 0.19% diphtheria toxoid (DT)
(1.25 or 0.5 Lf/mg microsphere), 0.15 or 0.06% tetanus toxoid (TT)
(0.5 or 0.2 Lf/mg microspheres), 0.05 or 0.02% pertusiss toxin (PT),
and 0.1 or 0.04% Haemophilus influenzae type b (Hib) as well as 5%
albumin. DT, TT and PT contents were determined by ELISA and
Hib by the Bial method.
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Anti-DT and -TT antibodies were determined by ELISA
using coating antigens from Welcome (Beckenham, UK: lots
BJGL 1004/F and MWC S208/A/F-6 and for DT and TT,
respectively). The results expressed in terms of an inhouse
guinea-pig reference standard (NIBSC code 98/572: 3.5 and
3.0 IU/mL nAb potency in vivo for DT and TT, respectively).
Geometric means were calculated from two independent
ELISA experiments on individual serum from each vaccine
group. Anti-PT antibodies were determined by an inhouse
method after coating plates with a PT from Smithkline
Beecham (Uxbridge, UK: lot PAC057). The results were ex-
pressed as the geometric mean relative to an inhouse refer-
ence serum assayed in the same plate. Finally, antibodies
against Hib polysaccharide polyribosyl ribitol phosphate
(PRP) were determined using, as coating antigen, oligosac-
charide conjugated human serum albumin (HbO-HA from
Wyeth Lederle; Pearl River, NY, USA). The results were
expressed as mean optical density (OD) from two sets of
experiments.
RESULTS
Hib, PT, and DT Exerted a Mutual Synergistic Influence
on Loading Efficiency When Coencapsulated. In monova-
lent PLGA 50:50 microsphere preparations, PT (30%) was
more efficiently entrapped than Hib (10%) (Table I). The
loading efficiency of Hib was improved when coencapsulated
with PT (16% Hib), with DT (29% Hib), or with both PT and
DT in a trivalent vaccine (59%Hib), the PT loading remained
unchanged with DT (31% PT), but increased to 75% in the
trivalent vaccine. By the same token, DT entrapment was 10
and 13% when coencapsulated with Hib and PT, respectively,
but rose to 59% when all three antigens were coencapsulated.
Hence, the coencapsulation of Hib, DT, and PT exerted a
synergistic effect on the loading efficiency of the individual
antigens.
Addition of Albumin to Multivalent Microsphere Vac-
cines Further Increased Antigen Loading. Albumin, which
has been reported to stabilise microencapsulated proteins
(11,15), was coencapsulated with selected antigen combina-
tions to yield a total nominal protein loading of 5%. Coen-
capsulation with albumin increased the entrapment efficiency
of Hib to approximately 80% in both divalent (with DT) and
trivalent (with DT and PT) vaccines (Table I). The effect was
even more striking for the loading of DT. Albumin improved
DT-loading efficiency to approximately, 90% for all three
combinations tested. The effect of albumin coencapsu-
lation on PT loading could not be assessed. The described
method for extracting PT from albumin-containing multiva-
Fig. 2. Anti-diptheria toxin (DT), anti-tetanus toxin (TT), anti-
pertussis toxin (PT) and anti-Haemophilus influenzae type b (Hib0
(d) antibodies in sera of guinea pigs after single injection of either of
two tetravalent microsphere-based vaccines (see Fig. 1 for further
details on vaccine formulations). The vaccination doses were 2.5 Lf
DT, 0.8 Lf TT, 0.8 g PT and 3.0 g Hib (when low nominal loading)
or 2.5 Lf DT, 0.8 Lf TT, 1.4 g PT and 2.1 g Hib (when high nominal
loading), as determined in vitro. For control of specific immunoge-
nicity, 2.5 Lf DT, 1 Lf TT, 1 g PT and 2 g Hib adsorbed on alum
was given once. The results illustrate the arithmetic means ± standard
errors (n  8–10). : alum-based control vaccine; ; microsphere-
based vaccine with high nominal antigen loading; : microsphere-
based vaccine with low nominal antigen loading.
Table I. Antigen Loading Efficiency and Burst Release (Measured after 24 h) of Haemophilus influenza Type b (Hib), Pertussis (PT), and
Diphtheria (DT) Antigens Encapsulated Individually or in Combinations into PLGA 50:50 Microspheres
Encapsulated
antigen
Loading efficiency (%) Burst release (%)
PT Hib DT PT Hib DT
PT 30 ± 2 — — 8 ± <1 — —
Hib — 10 ± <1 — — 41 ± 6 —
PT + Hib n.d. 16 ± 2 — n.d. 63 ± 2 —
PT + DT 31 ± 8 — 13 ± 3 19 ± 3 — 11 ± 2
PT + DT + BSA n.d. — 92 ± 15 n.d. — 8 ± 3
Hib + DT — 29 ± 1 10 ± 2 — 51 ± 8 49 ± 6
Hib + DT + BSA — 78 ± 18 90 ± 18 — 37 ± 5 5 ± 2
PT + Hib + DT 75 ± 3 59 ± 9 59 ± 7 8 ± 2 62 ± 6 12 ± 3
PT + Hib + DT + BSA n.d. 83 ± 14 89 ± 8 n.d. 14 ± 5 39 ± 8
Note: Loading efficiency represents the percentage (mean ± SD) of determined antigen content relative to the nominal loading, and the release
data represent the percentage of released antigen relative to the determined antigen loading. Nominal antigen loadings were 0.037% Hib,
0.050% PT, 1.48% DT, and 5% BSA. For Hib, ribosyl content was analyzed by the Bial assay, whereas PT and DT antigenicity were analyzed
by ELISA. n.d.: not detected.
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lent microspheres, for yet unknown reasons, was not appli-
cable to vaccines fabricated from the end-group capped
PLGA 50:50 polymer (as described below, this problem did
not appear when using the end-groups uncapped quality of
PLGA 50:50).
The Polymer Type Had Little Influence, Whereas Treha-
lose Improved Antigen Loading in Monovalent Vaccines. To
study the influence of other excipients on antigen loading,
we prepared microspheres with different polymer types that
contained trehalose (11,15) as stabilizer for the antigens.
PLGA 50:50 and the more hydrophobic PLA were individu-
ally loaded with PT and Hib. The polymer type did not affect
the encapsulation efficiency (Fig. 3). Moreover, coencapsula-
tion of 5% trehalose enhanced the entrapment of PT only
slightly from 30% to 35% for PLA, but from 30% to 53% for
PLGA 50:50 microspheres. This amount of trehalose had no
notable effect on the loading efficiency of Hib in PLA but
increased the entrapment from 10 to 14% in PLGA 50:50
microspheres. Higher trehalose concentrations (10–20%) did
neither improve further the loading efficiency of Hib in
PLGA 50:50 nor affect the loading in PLA microspheres
(data not shown).
Burst release of Antigens from Microspheres Generally
Depended on How Efficiently the Antigens were Encapsu-
lated. As a measure for the in vitro product quality, the
amount of antigen released during 24 h incubation in buffered
saline and 37°C was determined. Ideally, a limited fraction of
the antigen should be released from the microspheres imme-
diately for immunologic priming, whereas residual amounts
should be retained for later boosting. In this study, an in-
crease in the loading efficiency was typically related to a de-
crease in the burst release of both Hib and PT antigens. This
relationship showed inverse linear correlation with r2  0.7
and r2  0.9 for monovalent Hib (n  5) and PT (n  6),
respectively. The percentages of antigen released within the
initial 24 h from mono-, di- and trivalent preparations were
approximately 10–20% for PT, 40–60% for Hib, and 10–50%
for DT (Table I), and the coencapsulation of either albumin
(Table I) or trehalose (Fig. 3) lowered the burst release for all
three antigens.
Tetravalent Vaccines Were immunogenic in Guinea Pigs.
Two tetravalent PLGA 50:50 microsphere vaccines with dif-
ferent concentrations of DT, TT, PT, Hib, and 5% albumin
were prepared and tested both in vitro and in vivo; the nomi-
nal antigen loadings were lower than in the aforementioned
mono-, di- and trivalent preparations. Furthermore, since the
14 kDa end-group capped PLGA 50:50 (Resomer RG502) is
no longer available from Boehringer-Ingelheim, the tetrava-
lent vaccines were prepared with the corresponding end-
group uncapped PLGA 50:50 (Resomer RG502H). Al-
though the antigens were entrapped less efficiently in the
tetravalent Resomer RG502H than in the di- and trivalent
Resomer RG502, the loading efficiencies of all antigens gen-
erally increased with higher nominal antigen content (Fig. 1).
The effect was most evident for PT (66 vs. 27% for high and
low nominal antigen loading, respectively) and least for Hib
(53 vs. 49%) and resembled that observed for di- and trivalent
vaccines. The loading efficiencies for DT were 46 and 35%,
whereas those for TT were 37 and 29%.
Encouragingly, all antigens remained immunogenic, be-
cause high titers of persistent antibodies were raised in guinea
pigs after a single administration of either of the two tetra-
valent microsphere vaccines, as compared with the combined
formulation based on alum. The antibody kinetics followed a
similar pattern for all four antigens with a sharp increase in
antibodies the first 4 weeks after immunization, after which
antibodies slightly increased or persisted at a constant level
(Fig. 2). Both microsphere types with low and high nominal
content produced comparable results in terms of both kinetics
and maximum titers (p > 0.05 as analyzed on antibody titers
at 16 weeks). Whereas the anti-DT and anti-TT antibodies
typically declined after 4 weeks in animals that received the
control vaccine, the kinetics of anti-PT antibodies unexpect-
edly increased throughout the test period. The increase of
anti-Hib antibodies after 4 weeks was not significant (p > 0.05).
DISCUSSION
The availability of efficacious multivalent single-injection
vaccines would have a great impact on vaccination programs.
Fig. 3. Influence of polymer type (poly [d,l-lactic-coglycolic acid] vs. poly [d,l-lactic acid]) and the presence of the protein stabilising additive
trehalose (0 vs. 5%) on Haemophilus influenzae type b (left) and pertussis toxin (right) loading efficiency (filled bars) and burst release (open
bars) from monovalent microspheres. Hib content was determined by the Bial method and pertussis toxin by fluorimetry.
Multivalent Microsphere Vaccines 1333
We therefore examined the technological feasibility of using
polymeric microspheres for such vaccines by microencapsu-
lating Hib, PT, DT, and TT by spray-drying. The results sup-
ported our initial hypothesis that coencapsulation of several
antigens intrinsically improves loading efficiency of antigeni-
cally reactive antigens. Our hypothesis is based on the inter-
facial activity of proteins especially of albumin. At higher
protein concentration, a relatively smaller fraction of the total
protein is sufficient to saturate the W/O-interface during mi-
croencapsulation. This interfacial protein adsorption im-
proves the physical stability of the W/O-dispersion so that the
bulk fraction of protein is not exposed to the organic phase
and should remain intact. Most promising, tetravalent antigen
combinations were strongly immunogenic in guinea pigs.
Because little information is available on the microen-
capsulation of Hib and PT into polyester microspheres, we
initially studied these two antigens individually in PLA and
PLGA 50:50 polymers. Taking into account that Hib is con-
jugated to TT (approximately 1:3 ratio by weight), the loading
efficiency determined for Hib (10–15%) was surprisingly low,
because previous experiments had shown that up to 70% of
the nominal TT loading could be expected in PLGA 50:50
microspheres (11). This suggests a negative influence of the
polyribosyl-ribitol moiety on the encapsulation of Hib. How-
ever, it remains unknown whether this influence is linked
specifically to Hib or more generally to polysaccharide moi-
eties of proteins, because data on glycoprotein microencap-
sulation is unavailable. With respect to PT, filamentous hem-
agglutinin (FHA), pertactin, and PT have previously been
microencapsulated by solvent evaporation and tested for oral
and mucosal immunization (16,17), although only few details
were provided on the in vitro characteristics. For FHA-
containing microspheres, a loading efficiency of 60% (0.4%
nominal loading by weight), linear antigen release kinetics,
and a burst release of 10% were reported (17). More impor-
tantly also here, the microencapsulation process did not im-
pair the immunogenicity of the antigens, and the vaccines
were recently shown to protect mice against a respiratory
challenge with Bordetella pertussis (18). Because PT is con-
sidered the most important pertussis antigen for vaccination,
we choose it for inclusion in the multivalent microsphere-
based vaccines studied here. The results showed that PT was
more efficiently encapsulated than Hib (Fig. 3), but the two
polymer types did not differ in terms of antigen loading and
release.
The loading efficiencies of Hib and PT were improved by
coencapsulating trehalose (Fig. 3), which has been shown to
exert a positive effect on the microencapsulation of other
proteins (11). Trehalose may physically stabilise the W/O
emulsion during processing (19) and also hydrate preferen-
tially the protein, thereby increasing its conformational sta-
bility (20). Indeed, Hib and PT appeared physicochemically
intact within the given experimental parameters by assaying
encapsulated and released antigen. The Hib-toxoid conjugate
was assayed for its protein (fluorimetry) and polysaccharide
(Bial method) moieties, whereas the amount of fluorimetri-
cally detectable PT protein was compared with its antigenicity
in ELISA. Because the determined amounts of encapsulated
and released antigens did not vary with the assay method,
both Hib and PT most likely remained stable during the pro-
cesses (results not shown). However, for Hib the agreement
between the fluorimetric and colorimetric (Bial) data only
indicates that the protein and the polysaccharide moieties
were encapsulated and released to a comparable extent;
whether the two moieties were still conjugated remains un-
known. Although the in vivo data advocates for a stable Hib
conjugate, more discriminative assays are required for quan-
tification of the stability.
The main goal of this investigation was to study the fea-
sibility of coencapsulating several antigens in a single micro-
sphere formulation. Previously, proteinaceous additives, such
as albumin or gelatine, have been coencapsulated to improve
the biologic response of bioactive compounds including anti-
gens (4,15,21). Coencapsulation of several biologically active
compounds, such as cytokines or sub-unit antigens, provided
a tool to direct the immune response towards either a hu-
moral or cellular-type response (22,23) or to achieve a
broader immune response against a single infectious agent
(24,25). Our approach was to prepare a vaccine formulation
appropriate for concomitant stimulation of specific immune
responses against antigens derived from different pathogens.
The study provided encouraging data on the technological
feasibility of combining antigens in a microsphere vaccine,
because coencapsulated antigens remained antigenic and gen-
erally exerted a synergistic effect on loading efficiency. No
single antigen was superior to the others in improving total
antigen loadings. In addition, the coencapsulation of albumin
further increased antigen loadings (Table I). Proteinaceous
additives have previously been described to stabilise antigens
during microencapsulation and upon exposure to aqueous so-
lutions and elevated temperatures (11,14). We believe that
the improved entrapment of antigenic antigen was an unspe-
cific effect related partly to increased physical stability of the
W/O emulsion during encapsulation and partly to the higher
fraction of bulk antigen in the water phase that remained
protected from contact with the organic medium by the in-
terfacially adsorbed protein layer. Hence, the coencapsulated
proteins mutually stabilised each other and, thereby, en-
hanced the loadings of the individual antigenic proteins in the
microspheres as ascertained for DT, TT, and PT by antige-
nicity testing.
Despite different views as to which type of release kinet-
ics is most preferable, antigen-burst release is an important
aspect in the development of microspheres. Extracellular an-
tigens in solution are normally unavailable for uptake and
presentation by antigen-presenting cells after parenteral ad-
ministration and may even induce tolerance. Hence, less ef-
ficient priming might be anticipated from antigen released
extracellularly during the priming phase. It is also a notion
that the number of surviving memory cells is directly propor-
tional to the number of precursor cells activated during the
priming phase of the immune response (26). Hence, one
might prefer low-burst release to facilitate intracellular anti-
gen release after phagosomal particle uptake and degradation
in the phagolysosomal fusion product. Furthermore, long-
term release of antigens from microspheres is difficult to
monitor and even harder to interpret in terms of biological
significance. Therefore, we decided to analyze the release be-
havior of the microspheres only in the initial phase. The
amounts of released antigen determined after 24 h for the
mono- and multivalent microspheres depended on both anti-
gen and excipients. Burst-release values were in the range of
10–50% of the actual antigen content and considered accept-
able in view of estimated amounts necessary for priming vs.
Boehm et al.1334
boosting in vivo. We observed a trend towards lower burst
release with increasing loading efficiency for Hib in multiva-
lent microspheres. However, it occurred that multivalent mi-
crospheres showed higher initial release rates than monova-
lent formulations. A possible explanation for this effect might
be the higher nominal protein loadings of the multivalent
microspheres creating a more porous microsphere matrix: the
higher the protein concentration in the microspheres, the
larger the absolute amount of protein near the surface avail-
able for release. Upon release of molecules located near the
particle surface, pores are formed which may favor the release
of additional fractions of protein.
Although the present study did not directly compare
mono- and multivalent vaccines in vivo, we clearly demon-
strated that a tetravalent vaccine based on biodegradable mi-
crospheres is feasible. After single administration of micro-
spheres loaded with DT, TT, PT, and Hib, high titers of last-
ing antibodies against all four antigens were detected in
guinea pig sera. The kinetics and magnitude of the immune
response against the individual antigens differed only slightly
as a function of formulation, i.e., alum vs. microspheres, low-
vs. high-antigen loading. Because the purpose of the present
study was to test the technological properties and the immu-
nological feasibility of multivalent vaccines based on biode-
gradable microspheres, this primary experimental design did
not permit us to study whether these differences in immuno-
genicity were significant or whether they were related to dif-
ferential antigen stability or release characteristics, to the
number of particles injected or to the differences in absolute
and relative antigen contents. Also, to what extent these vac-
cines can generate protective immune responses is presently
unknown and should be addressed in further testing of mul-
tivalent microsphere vaccines. Nevertheless, the levels of anti-
TT and anti-DT antibodies suggest protective immunity, be-
cause the ELISA antibodies detected with the described
method normally correlates well with neutralising antibodies
(M.P. and D.S., unpublished observations) for which protec-
tion levels are 0.1 IU/mL for both TT and DT.
In a previous investigation with a divalent tetanus-
diphtheria microsphere vaccine in rats, monovalent DT (2) or
TT (3) microspheres produced stronger immune responses
than did the divalent vaccine. This phenomenon was ascribed
to antigenic competition between the two antigens, resulting
in reduced antigen presentation. However, no immunological
interactions were observed when guinea pigs were immunized
with mixtures of DT and TT embedded individually in differ-
ent microsphere populations, which were mixed prior to im-
munization (M.P. and D.S., unpublished observations). It has
also been reported that the presence of more than one anti-
gen in a conventional multivalent vaccine may result in re-
duced immunogenicity for all of the antigens (8) and that the
capacity of the organism to deal efficiently with several anti-
gens at the same time might be limited (27). The present study
demonstrated that both the encapsulation efficiency and the
correlation between antigen content, determined in vitro, and
the immunological reactivity in animals depended on the spe-
cific antigen. Hence, combination of antigens requires careful
and systematic monitoring of both in vitro and in vivo param-
eters, and an objective of future immunization tests should be
made to reevaluate the optimal antigen doses required to
induce adequate immune responses against the coencapsu-
lated antigens.
Summing up, in this investigation, we discuss potential
technological and immunological benefits of multivalent mi-
crosphere vaccines. Evidence for the feasibility of the encap-
sulation of Hib and PT in polymeric microspheres as well as
of multivalent combinations of Hib, PT, DT, and TT was
provided. The coencapsulation of antigens was particularly
beneficial as it improved the entrapment efficiency of the
individual antigens in a physicochemically and antigenically
stable form, which was further improved by coencapsulating
albumin. The fact that all antigens were strongly immuno-
genic in guinea pigs is encouraging in view of simplifying and
improving vaccination procedures. It is our hope that this
study may contribute to bias this technology towards perhaps
clinical evaluation.
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